Early therapeutic effects of adaptive servo-ventilation on cardiac sympathetic nervous function in patients with heart failure evaluated using a combination of $^{11}$C-HED PET and $^{123}$I-MIBG SPECT

Yusuke Tokuda, MD, a Mamoru Sakakibara, MD, PhD, b Keiichiro Yoshinaga, MD, PhD, FACC, FASNC, c Shiro Yamada, MD, PhD, d Kiwamu Kamiya, MD, PhD, a Naoya Asakawa, MD, PhD, a Takashi Yoshitani, MD, PhD, e Keiji Noguchi, MD, PhD, a Osamu Manabe, MD, PhD, f Nagara Tamaki, MD, PhD, f and Hiroyuki Tsutsui, MD, PhD g

a Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
b Department of Cardiovascular Medicine, Tokyo Tenshi Hospital, Tokyo, Japan
c Diagnostic and Therapeutic Nuclear Medicine, National Institute of Radiological Sciences, Chiba, Japan
d Department of Cardiovascular Medicine, Otaru Kyokai Hospital, Otaru, Japan
e Department of Cardiovascular Medicine, Hakodate Neurosurgery Hospital, Hakodate, Japan
f Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
g Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Received Jul 6, 2017; accepted Oct 31, 2017
doi:10.1007/s12350-017-1132-4

Rationale. Adaptive servo-ventilation (ASV), a novel respiratory support therapy for sleep disorders, may improve cardiac function in heart failure (HF). However, the reasons that ASV improves cardiac function have not been fully studied especially in sympathetic nervous function (SNF). The purpose of the present study was to investigate the effects of ASV therapy on cardiac SNF in patients with HF.

Methods. We evaluated ASV therapeutic effects before and 6 months after ASV therapy in 9 HF patients [57.3 ± 17.3 years old, left ventricular ejection fraction (LVEF) 36.1 ± 16.7%]. We performed echocardiography, polysomnography, biomarkers, $^{11}$C-hydroxyephedrine (HED) PET as a presynaptic function marker and planar $^{123}$I-metaiodobenzylguanidine (MIBG) to evaluate washout rate.

Results. ASV therapy reduced apnea-hypopnea index (AHI) and improved plasma brain natriuretic peptide (BNP) concentration. In $^{123}$I-MIBG imaging, the early heart/mediastinum

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12350-017-1132-4) contains supplementary material, which is available to authorized users. The authors of this article have provided a PowerPoint file, available for download at SpringerLink, which summarises the contents of the paper and is free for re-use at meetings and presentations. Search for the article DOI on SpringerLink.com.

Funding This study was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (No. 23591024).

Reprint requests: Keiichiro Yoshinaga, MD, PhD, FACC, FASNC, Diagnostic and Therapeutic Nuclear Medicine, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-Ku, Chiba 263-8555, Japan; yoshinaga.keiichiro@qst.go.jp

1071-3581/17/$34.00

Copyright © 2017 The Author(s). This article is an open access publication
(H/M) ratio increased after ASV therapy (2.19 ± 0.58 to 2.40 ± 0.67; \(P = 0.045\)). Washout rate did not change (23.8 ± 7.3% to 23.8 ± 8.8%; \(P = 0.122\)). Global \(^{11}\)C-HED retention index (RI) improved from 0.068 ± 0.033/s to 0.075 ± 0.034/s (\(P = 0.029\)).

**Conclusions.** ASV reduced AHI and improved BNP. ASV might initially improve presynaptic cardiac sympathetic nervous function in HF patients after 6 months of treatment. (J Nucl Cardiol 2019;26:1079–89.)

**Key Words:** \(^{11}\)C-hydroxyephedrine • \(^{123}\)I-metaiodobenzylguanidine • adaptive servo-ventilation • cardiac sympathetic nerve function • heart failure • tomography

### Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| ASV          | Adaptive servo-ventilation |
| BNP          | Brain-type natriuretic peptide |
| HED          | \(^{11}\)C-hydroxyephedrine |
| HF           | Heart failure |
| LVEF         | Left ventricular ejection fraction |
| MIBG         | \(^{123}\)I-metaiodobenzylguanidine |
| PET          | Positron emission tomography |
| RI           | Retention index |
| SNF          | Sympathetic nervous function |
| SPECT        | Single-photon emission computed tomography |

**See related editorial, pp. 1090–1092**

### INTRODUCTION

Sympathetic nervous function (SNF) is an important compensatory mechanism to maintain cardiovascular homeostasis in chronic heart failure (HF).\(^1,2\) However, continuous activation of cardiac SNF induces myocardial remodeling through increased active oxygen uptake and alters the signal transduction system of the beta-adrenergic receptor, resulting in increased long-term mortality in HF.\(^3\) Angiotensin-converting enzyme inhibitors,\(^4\) angiotensin receptor blockers,\(^5\) beta-blockers,\(^6\) and aldosterone antagonists\(^7\) are thought to inhibit myocardial remodeling induced by cardiac SNF, by acting as neurohormonal antagonists, and to improve long-term mortality in patients with HF.

Sleep-related breathing disorders are one of the comorbidities that worsen HF via inducing alterations in loading conditions, hypoxia, and SNF activation.\(^8,9\) Continuous positive airway pressure (CPAP) treatment has been shown to improve cardiac function in patients with HF and obstructive sleep apnea.\(^8\) Adaptive servo-ventilation (ASV) has also been reported to improve cardiac function and may be a promising non-pharmacological strategy for the treatment of HF.\(^10,11\) However, the effects of ASV on HF patients have not been established.\(^12,13\) A previous study reported that abnormal breathing patterns in HF patients were regulated with ASV by enhancing pulmonary vagal afferents, resulting in suppression of SNF.\(^14\) Additionally, ASV could convert rapid shallow breathing patterns to slow regular breathing patterns and prevent respiratory oscillations in HF patients, which could also inhibit cardiac SNF.\(^14,15\) Therefore, the evaluation of cardiac SNF is essential to determining the therapeutic mechanisms behind ASV in HF.

\(^{123}\)I-metaiodobenzylguanidine (\(^{123}\)I-MIBG) single-photon and \(^{11}\)C-hydroxyephedrine positron emission tomography (\(^{11}\)C-HED PET) have enabled the assessment of cardiac sympathetic nerve function (SNF).\(^16,17\) \(^{123}\)I-MIBG planar imaging is considered a standard approach to evaluating cardiac SNF and predicting prognosis in HF patients.\(^18–22\) The properties of MIBG allow for it to be used to measure not only the heart/mediastinum (H/M) ratio as a presynaptic function marker but also the washout rate as a partial reflection of norepinephrine (NE) turnover parameter of SNF.\(^13\) Koyama et al. evaluated the therapeutic effects of ASV using \(^{123}\)I-MIBG imaging. It is well known that \(^{123}\)I-MIBG imaging has insufficient image quality and the accuracy of semi-quantitative parameters is suboptimal. In contrast, \(^{11}\)C-HED PET has emerged as a novel modality providing a high-quality image and it can be used to accurately quantitatively evaluate cardiac SNF including the retention index (RI).\(^17,23,24\) However, \(^{11}\)C-HED PET cannot be used to assess the washout rate because of its short physical half-life.\(^25\) Using combined \(^{11}\)C-HED PET and \(^{123}\)I-MIBG imaging, it should be possible to measure precise presynaptic cardiac sympathetic nervous function and sympathetic turnover. Accordingly, we examined the effects of ASV therapy on cardiac SNF using \(^{11}\)C-HED PET as a quantitative presynaptic function parameter and \(^{123}\)I-MIBG imaging as a partial reflection of NF turnover parameter in patients with HF.

### METHODS

#### Study Population

Eleven consecutive patients with chronic HF were prospectively enrolled in the current study at Hokkaido University Hospital between August 2010 and August 2013. HF was defined as New York Heart Association function (NYHA) class II or III, left ventricular ejection fraction (LVEF) < 50%, and plasma brain-type natriuretic peptide (BNP) concentration > 100 pg/mL. Major exclusion criteria...
included uncontrolled decompensated HF, active ischemic heart disease with exertion chest pain and requiring coronary revascularization, severe pulmonary disease, neurological or musculoskeletal disease, severe valvular regurgitation, stroke, respiratory failure, end-stage renal disease treated by hemodialysis, and inability to tolerate ASV. All patients had received optimal medical therapy to stabilize their symptoms and signs of HF before participating in the study.

The study was approved by the Ethics Committee of Hokkaido University Hospital. All participants provided written informed consent.

Study Design

Patients received nocturnal ASV treatment for 6 months. Pharmacological therapy was not changed during the study period. ASV (AutoSet CS; Teijin Pharma, Tokyo, Japan) was used without oxygenation and administered via a fitted nasal mask (Teijin Pharma) in the default mode, with expiratory positive airway pressure of 5 cmH\(_2\)O and inspiratory positive airway pressure of 3–10 cmH\(_2\)O. We instructed the patients to use ASV > 4 h per night during the study period. Data regarding compliance of ASV and effectiveness were stored in the device, downloaded and analyzed. Adequate adherence to ASV was defined as > 4 hours per night.\(^{13}\) We performed \(^{11}\)C-HED PET/computed tomography (CT), \(^{123}\)I-MIBG imaging, laboratory tests, polysomnography, and echocardiography in all patients before and after 6 months of ASV treatment. All the imaging data obtained before and after ASV therapy were blindly analyzed in order to avoid interpreter bias.

Blood and Urine Biochemistry

Plasma concentrations of BNP and norepinephrine and the urinary concentration of norepinephrine were measured at baseline and after 6 months of ASV treatment.

Overnight Polysomnography

Patients underwent overnight polysomnography using a cardiopulmonary monitoring device (Morpheus; Teijin Limited, Tokyo, Japan) comprising a pressure sensor for nasal flow, two stress-sensitive belts for the ribcage and abdomen, and a continuous pulse oximeter.\(^{26,27}\)

Echocardiography

We measured left ventricle (LV) end-diastolic dimension, LV end-systolic dimension, LVEF, interventricular septal thickness, LV posterior wall thickness, and the ratio between early and late diastolic transmural flow velocity using echocardiography (Apio Artida SSH-880-CV or Apio SSA-770A; Toshiba Medical Systems, Tochigi, Japan). We also measured the ratio of maximal early diastolic filling wave velocity to maximal early diastolic myocardial velocity, and deceleration time. LVEF was measured from apical four- and two-chamber images using the biplane method of disks.

\(^{123}\)I-MIBG Imaging

Patients received 111 MBq of \(^{123}\)I-MIBG (FUJIFILM R1 Pharma, Tokyo, Japan) at rest under fasting conditions.\(^{23}\) Fifteen minutes and 4 h after the \(^{123}\)I-MIBG injection, planar images and SPECT data acquisitions were performed using a dual-head scanner (Millennium MG; Elgems, Tirat Carmel, Israel). Whole cardiac \(^{123}\)I-MIBG uptake was measured as the H/M ratio using a planar image. The region of interest (ROI) was manually traced for the whole LV and a rectangular ROI was placed in the upper mediastinum in the early image.\(^{18}\) Rectangular ROIs of 9 × 9 pixels were placed in the upper 30% of the lung vertical length. The same ROI was applied for the delayed \(^{123}\)I-MIBG planar image. The H/M ratio was calculated by dividing the count density of the whole heart by that of the mediastinum, and standardized using the calibration phantom method.\(^{28}\) We calculated the washout ratio using the following equation:

\[
\text{washout rate} = \frac{[H-M]_{15 \text{ min}} - [H-M]_{4 \text{ h}}}{[H-M]_{15 \text{ min}}} \\
\text{where } H = \text{mean counts per pixel in the left ventricle and } M = \text{mean counts per pixel in the upper mediastinum}.\(^{29,30}\)
\]

Although we obtained \(^{123}\)I-MIBG imaging data with planar and SPECT, we did not use SPECT data for evaluation. We did not apply a physical decay correction for the H/M calculation and the method of washout rate.

\(^{11}\)C-HED PET/CT Imaging

\(^{11}\)C-HED was produced from \([^{11}\text{C}]\) methyl iodide and metaraminol (free base) using standard methods with high purity and high specific activity. Patients were instructed to fast overnight.\(^{11}\)C-HED PET/CT imaging was performed with a 64-slice PET/CT scanner (Biograph Siemens/CTI, Knoxville, TN). Low-dose CT was also performed for attenuation correction. CT co-registered standard orthogonal PET images were re-sliced into series of short-axis, horizontal long-axis, and vertical long-axis images.

Immediately after intravenous administration of 5 mCi (185 MBq) \(^{11}\)C-HED, 40-min three-dimensional list-mode PET acquisition was performed.\(^{30}\) Images were reconstructed using filtered back correction with a 12-mm Hann filter and were reconstructed into 23 frames (10 × 10, 1 × 60, 5 × 100, 3 × 180, and 4 × 300 seconds).\(^{23}\) During analysis, regional \(^{11}\)C-HED PET/CT uptake was assessed using the 17-segment model recommended by the American Society of Nuclear Cardiology. Then, the LV wall was subdivided into four segments: anterior, septum, inferior, and lateral wall. The \(^{11}\)C-HED RI was calculated as

\[
\text{Retention index} = \frac{\text{Tissue activity(30 – 40 min)}}{f_0 \text{ blood activity}}
\]

This equation yields a value for the RI based on mean tracer counts within the myocardial ROI between 30 and 40 min divided by the integrated metabolite-corrected time-plasma radioactivity curve from 0 to 40 min after injection.\(^{24,31}\) Mean RI of all slices was taken as the measure of \(^{11}\)C-HED retention. The LV wall was divided into 17 segments based on ASNC guidelines using in-house software.\(^{30,32}\) Then,
we divided these 17 segments into four territories (anterior, septum, inferior, and lateral wall) and calculated the mean value in each region (Figure 1).^{23}

**Statistical Analysis**

Values are mean ± standard deviation. Categorical variables are presented as frequencies with percentages. Since BNP levels showed non-linearity, plasma BNP levels were calculated using log-transformation.^{30} We analyzed data distribution using Shapiro-Wilk tests. Continuous variables with normal distribution at baseline and after ASV treatment were compared using the paired t-test. In case of non-normal distribution, we applied the Wilcoxon signed-rank test to evaluate the statistical differences between measurements at baseline and 6 months after the ASV therapy. A $P$ value $< 0.05$ was considered statistically significant. All analyses were performed using JMP 11.0 (SAS Institute, Cary, NC).

**RESULTS**

**Patient Characteristics**

We enrolled total 11 HF patients who met the inclusion criteria. Among 11 patients, 2 patients did not use ASV > 4 hours per night. Therefore, 9 patients completed the study protocol, and we analyzed these 9 patients in the current study.

The underlying causes of HF were dilated cardiomyopathy in five patients (55.6%), dilated hypertrophic cardiomyopathy in one patient (11.1%), ischemic cardiomyopathy in one patient (11.1%), and others in two patients (22.2%). NYHA functional class was II in six patients (66.7%) and III in three patients (33.3%). Mean LVEF was 36.1 ± 5.3% ranging from 22% to 48%. Medical treatment included angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in nine patients (100%), beta blockers in nine patients (100%), and diuretics in six patients (66.7%) (Table 1). Among the nine patients, six met the criteria for sleep apnea, with an apnea-hypopnea index (AHI) of greater than 15.^{14,26} Among these 6 patients, 5 patients were obstructive sleep apnea and one patient was central sleep apnea. Mean AHI was 22.3 ± 14.4/h, and mean 3% oxygen desaturation index was 20.3 ± 14.7/h at baseline. AHI means numbers of apnea and hypopnea per hour. AHI reflects the severity of sleep apnea disorders and AHI > 15 is defined as sleep apnea.^{26} AHI ranged from 15 to 30 is defined as moderate sleep apnea.^{30} The oxygen desaturation index (ODI) has been used to identify screening tools for sleep apnea. ODI is calculated as drop in oxygen saturation greater than equal 3% in comparison with immediately preceding basal value. We did not change medical therapy through the 6 months of this study.

**ASV Treatments**

Clinical characteristics at baseline and after 6 months of ASV treatment are shown in Table 2. Mean daily use of ASV was 4.8 ± 0.7 hours. AHI was significantly decreased (22.3 ± 14.4 to 1.9 ± 4.1/h; $P = 0.040$) and minimum peripheral oxygen saturation increased (83.1 ± 8.3 to 91.0 ± 3.3%; $P = 0.016$).

![Figure 1. Representative images of 27-year-old female with $^{123}$I-MIBG planar/SPECT and $^{11}$C-HED PET/CT. A Short-axis images of $^{123}$I-MIBG SPECT and $^{11}$C-HED PET/CT. B Planar images of $^{123}$I-MIBG and polar map images of $^{11}$C-HED PET/CT. a Early $^{123}$I-MIBG SPECT images at baseline. b $^{123}$I-MIBG SPECT images after 6 months of ASV. c Delayed $^{123}$I-MIBG SPECT images at baseline. d Delayed $^{123}$I-MIBG images after 6 months of ASV. e $^{11}$C-HED PET images at baseline. f $^{11}$C-HED PET images after 6 months of ASV. Representative case of 27-year-old female with heart failure with improved AHI (15.6 to 0.5/h) and LVEF (38.0 to 45.0%) after ASV therapy. Global $^{11}$C-HED PET/CT RI, a presynaptic function marker of SNF, significantly improved after ASV treatment (Figure 1B-e, 1B-f after ASV). The early H/M ratio also increased (Figure 1B-a at baseline; and 1B-b after ASV), whereas the delayed H/M ratio, a turnover parameter of SNF, did not change (Figure 1B-c at baseline; and 1B-d after ASV). ASV, adaptive servo-ventilation; HED, $^{11}$C-hydroxyephedrine; $^{123}$I-MIBG SPECT, $^{123}$I-metaiodobenzylguanidine single-photon emission computed tomography; PET, positron emission tomography; H/M, heart/mediastinum; RI, retention index; SNF, sympathetic nervous function; LVEF, left ventricular ejection fraction.](image-url)
Effects of ASV

There were no significant changes in heart rate and systolic or diastolic blood pressure (Table 2). LVEF tended to increase (36.1 ± 5.3 to 39.2 ± 5.1%; \( P = 0.096 \)). LV end-diastolic volume (180.2 ± 95.2 to 160.9 ± 81.8 mL; \( P = 0.217 \)) and LV end-systolic volume (122.3 ± 86.3 to 107.4 ± 72.4 mL; \( P = 0.272 \)) tended to decrease after the ASV therapy. In addition, plasma and urinary norepinephrine concentrations did not change before and after ASV treatment (Table 2). The log plasma BNP concentration significantly decreased (\( P = 0.048 \)) after ASV treatment.

Effects of ASV on Cardiac SNF

In \(^{123}\text{I}-\text{MIBG}\) scintigraphy, the early H/M ratio significantly increased (2.19 ± 0.58 to 2.40 ± 0.67; \( P = 0.045 \)) (Figures 1 and 2). The delayed H/M ratio and washout rate did not change before and after 6 months of ASV treatment (delayed H/M ratio: 2.07 ± 0.61 to 2.22 ± 0.66; \( P = 0.245 \), washout rate: 23.8 ± 7.3% to 23.8 ± 8.8%; \( P = 0.122 \)). The whole LV \(^{11}\text{C}-\text{HED}\) RI significantly increased (0.068 ± 0.033/s to 0.075 ± 0.034/s; \( P = 0.029 \)) after ASV treatment. In addition, the RI significantly increased in the anterior region (0.070 ± 0.034/s to 0.090 ± 0.045/s; \( P = 0.035 \)), and decreased in the septal region (0.067 ± 0.035/s to 0.061 ± 0.032/s; \( P = 0.040 \)) (Figure 3). There were no significant changes in the RI in the inferior or lateral regions.

**DISCUSSION**

ASV treatment for 6 months improved AHI and plasma BNP levels. It also improved global LV and...
anterior presynaptic function but did not change the $^{123}$I-MIBG imaging washout rate in HF patients.

Effects of ASV

Apnea-hypopnea index (AHI) means numbers of apnea and hypopnea per hour. AHI reflects the severity of sleep apnea disorders and AHI > 15 is defined as sleep apnea. Based on the American Academy of Sleep Medicine (AASM) criteria, AHI ranged from 15 to 30 is defined as moderate sleep apnea. In the current study, mean AHI was 22.3 ± 14.4/h. Although 3 patients were not defined as sleep apnea, the patients having sleep apnea may have been categorized as moderate severity. ASV treatment decreased the AHI in agreement with results of previous studies. However, there was no significant difference between the baseline and after ASV treatment. The average use of ASV was 4.8 ± 0.7 h per night, showing good compliance of ASV during the study period. Sufficient use of ASV per night likely contributed to the decrease in AHI. Although there was no significant different, LV remodeling parameters such as LVEDV and LVESV decreased 6 months after the ASV treatment. The tendency of ASV treatment effects on LVEF and LV remodeling parameters after the ASV treatments of the current study agree with previous study by Koyama et al. In terms of severity of sleep disorder,

Figure 2. Changes in early H/M ratio, washout rate, and retention index after ASV treatment. A Early H/M ratio of $^{123}$I-MIBG before and after ASV treatment. B Delayed H/M ratio of $^{123}$I-MIBG before and after ASV treatment. C Washout rate of $^{123}$I-MIBG before and after ASV treatment. D Retention index of $^{11}$C-HED PET/CT before and after ASV treatment. All abbreviations are the same as in Figure 1. Mean ± SD of each parameter: Early H/M ratio of $^{123}$I-MIBG (baseline: 2.19 ± 0.58, after ASV: 2.04 ± 0.67), Delayed H/M ratio of $^{123}$I-MIBG (baseline: 2.07 ± 0.61, after ASV: 2.22 ± 0.66), Washout rate of $^{123}$I-MIBG (baseline: 23.8 ± 7.3%, after ASV: 23.8 ± 8.8%), Retention index of $^{11}$C-HED PET/CT (baseline: 0.068 ± 0.033/s, after ASV: 0.075 ± 0.034/s).
the previous study by Koyama enrolled more severe sleep apnea patients (AHI 35.7 ± 13.7/h) than that of the current study (22.3 ± 14.4/h). The difference of patients background may have had impacts on the differences between the current study and previous study by Koyama et al. This difference may have also had impacts on the neurohormonal parameter changes. In addition, log BNP significantly decreased after 6 months of ASV therapy. Though there are some differences, overall these results agree with those of previous studies using ASV in HF.13,36

Presynaptic Function and Washout Parameter

Among recent applications of diagnostic, imaging is the non-invasive evaluation of cardiac SNF in HF patients. In particular, both 123I-MIBG imaging and 11C-HED PET are useful modalities for non-invasive evaluation for cardiac SNF.18 It has been reported that the evaluation of cardiac SNF through 123I-MIBG imaging can be used to stratify risk in patients with HF. The low H/M ratio as determined through 123I-MIBG planar images can predict sudden cardiac death in HF regardless of LVEF.37 Optimal medical therapy and cardiac resynchronization therapy have also been reported to improve cardiac SNF, as evaluated by 123I-MIBG imaging, and to reduce mortality in HF patients.38 In a recent 123I-MIBG imaging study, Koyama et al reported that ASV therapy ameliorated SNF in HF patients.13 It appears that 123I-MIBG imaging is a reliable diagnostic tool for evaluating cardiac SNF and prognosis in HF. In those studies, most investigators have used planar cardiac images and made semi-quantitative assessment of global LV sympathetic nervous function such as the H/M ratio and washout rate.39-41

11C-HED PET/CT has emerged as a new modality to evaluate cardiac SNF. It has a high spatial resolution and can also be used to accurately quantify cardiac SNF at both the LV global and regional levels. In particular,
the RI in $^{11}$C-HED PET has been closely correlated with cardiovascular events in HF. These accurate quantitative parameters are a major advantage of $^{11}$C-HED PET/CT.

As the physical short half-life of $^{11}$C-HED is 20 min, $^{11}$C-HED cannot provide washout parameters as $^{123}$I-MIBG imaging can. The ideal SNF measurements would be precise quantifications with uptake as well as washout parameters. No imaging tool has been established to achieve this goal. In this regard, we evaluated the effects of ASV on SNF using $^{11}$C-HED PET as a quantitative marker of presynaptic function, and $^{123}$I-MIBG imaging as a washout parameter in the current study regarding to previous studies. This is a relatively new concept for SNF measurements applied for therapeutic effects of ASV, which takes the previous study by Koyama et al. further.

We found that the global $^{11}$C-HED PET/CT RI improved after 6 months of ASV therapy. The early H/M ratio also significantly increased, a finding that aligns with those of a previous study. In addition to performing semi-quantitative H/M ratio measurement using $^{123}$I-MIBG imaging, we confirmed previous reports using precise quantitative assessment using $^{11}$C-HED PET/CT. Reduced AHI from using ASV may have contributed to improving presynaptic sympathetic nervous function. In contrast, the delayed H/M ratio and washout rate did not change in $^{123}$I-MIBG imaging. The reasons for this finding are unclear. It is possible that improvements in $^{123}$I-MIBG washout appear later than do improvements in presynaptic function via uptake-1. This means that both global $^{11}$C-HED PET RI and the early H/M ratio determined by $^{123}$I-MIBG may indicate improvements of presynaptic cardiac SNF during the early phase of ASV therapy in HF patients. Long-term observational studies are required to confirm this hypothesis. The early H/M did not reach statistically significant improvement but the mean value was improved after the ASV therapy in the current study. Thus, another possible explanation for this discrepancy could be the small sample size of the current study.

Regional Sympathetic Nervous Function

In the current study, ASV therapy improved cardiac sympathetic function in the anterior LV region as well as global LV SNF based on $^{11}$C-HED PET/CT data. This finding provides additional insights beyond those of the previous study by Koyama et al. Improvement of cardiac SNF in the anterior LV may be associated with innervation within the heart. Regional patterns of myocardial sympathetic denervation have been observed in patients with dilated cardiomyopathy, diabetic autonomic neuropathy, and prior myocardial infarction with SNF measured by $^{11}$C-HED PET, with the lowest RI reported in the inferoapical region. In animal studies, the anterior region of the LV was found to be the most densely innervated with sympathetic fibers, and the concentration of catecholamine was the highest at the anterior and basal LV walls. We found the beneficial effects of ASV therapy on cardiac SNF in the anterior region. The denser sympathetic innervation of this area may be the mechanism behind the changes in cardiac SNF with ASV therapy, which lead to easier detection by $^{11}$C-HED PET/CT. In contrast, among 9 cases, 4 cases actually reduced HED RI in septum. In HF patients, increased LV end-diastolic pressure and associated pulmonary edema will cause pulmonary hypertension, and the septum is stretched to become dysfunctional by making the helix fibers more transverse. Furthermore, as the left ventricle becomes dilate, the septum will encroach on the RV cavity in the chronic period. Therefore, the left ventricular septum could be more susceptible to damage than other left ventricular wall due to the left ventricular pressure and volume loading. These specific function and structural elements of the septum may be closely related to SNF functional change. However, the magnitude of improving anterior RI was bigger than that of RI reduction in septum (31.4 ± 46.1% vs −6.4 ± 14.5%). As a result, whole LV sympathetic nervous activity improved after the ASV therapy in the current study.

Study Limitations

This study was a single-center study with a small sample size. While the number of patients was small, PET measurements can provide segment-by-segment assessment of absolute RI. When combined with a repeated measures analysis, in which each myocardial segment within each patient can serve as its own control, the study design may provide a valid assessment of the effects of ASV therapy despite the limited sample size. A similar sample size was used in previous studies evaluating sympathetic nervous function changes after therapeutic interventions using $^{11}$C HED PET. Despite the relatively small sample size, the change in sympathetic nervous function after the ASV measurements by $^{11}$C HED PET and $^{123}$I MIBG scintigraphy was demonstrated. However, the small sample size may have had impacts on the data with early H/M and washout rate. In this regard, a larger population is required to confirm the results. The extent to which improvements in cardiac SNF influence prognosis in patients with HF treated with ASV is not known. Cowie et al. reported that ASV therapy did not influence mortality in patients with chronic HF and central sleep...
apnea. However, a close look at the study population reveals that there are some significant differences between the SERVE-HF trial, the current study and the previous study by Koyama et al. The SERVE-HF trial seems to include end-stage HF patients such as those in NYHA functional class 4. Second, over 50% of the enrolled population in the SERVE-HF trial had HF due to coronary artery disease. In the study by Koyama et al. and the current study, most of the patients had NYHA class 2 HF and mildly to moderately reduced LVEF, possibly indicating that these populations may still have viable myocardium that can respond to specific new or additional treatment including ASV. In contrast, the study population in the SERVE-HF trial seemed not to have sufficient viable myocardium that could respond to the additional treatment. In addition, patients with HF due to CAD may have extensive scarring which may also contribute to a diminished response to new treatments. Despite these differences, ASV may still be able to improve cardiac function in patients with mild-to-moderate HF not caused by CAD. In this regard, improvement to cardiac sympathetic nervous function may be one of the key factors for therapeutic effects. The study populations in the current study and in the previous study by Koyama et al. are small. Therefore, as a next step, we would definitely need a larger clinical trials to test this hypothesis. Our findings suggest that ASV improves cardiac SNF in HF patients, but we cannot draw any conclusions about their long-term prognosis.

CONCLUSIONS

ASV reduced AHI in HF patients. Early $^{123}$I-MIBG H/M ratio and $^{11}$C-HED RI significantly improved, whereas $^{123}$I-MIBG washout ratio did not change with ASV. A comprehensive approach using a combination of $^{11}$C-HED PET and $^{123}$I-MIBG imaging could be used to evaluate cardiac SNF and provide regional and global SNF uptake parameters and global washout parameters in HF patients. ASV therapy may mediate its beneficial effects in HF by initially improving presynaptic SNF.

NEW KNOWLEDGE GAINED

The combined use of $^{11}$C-HED PET and $^{123}$I-MIBG imaging may play a role in the detection of presynaptic cardiac sympathetic nervous function for the evaluation of new heart failure therapy.

Acknowledgments

The authors thank Keiichi Magota, PhD, Eriko Suzuki, Natsue Ito, and Ken-ichi Nishijima, PhD, for their technical expertise during this study. This manuscript has been reviewed by a North American English-language professional editor, Ms. Holly Beanlands. The authors also thank Ms. Holly Beanlands for critical reading of the manuscript.

Disclosure

Hi Tsutsui has received speakers’ bureau/honoraria from MSD Corp.; Ono Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Company, Limited; Mitsubishi Tanabe Pharma Corporation; Daiichi-Sankyo Company, Limited; Teijin Pharma Limited; Nippon Boehringer Ingelheim Co., Ltd.; Bayer Yakuhin, Ltd.; Pfizer Inc.; Bristol-Myers Squibb Company; and research funds from Takeda Pharmaceutical Company Limited; Nippon Boehringer Ingelheim Co., Ltd.; Mitsubishi Tanabe Pharma Company, Limited; Daiichi-Sankyo Company, Limited; and consultation fees from Novartis Pharmaceuticals; Ono Pharmaceutical Co., Ltd.; and Pfizer Inc. K. Yoshinaga has received research grants from A&D Company, Ltd. and Nihon Medi-Physics Co., Ltd. N. Tamaki has received research grants from FUJIFILM RI and Nihon Medi-Physics. All other authors declare no conflicts of interest related to this article.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257–63.
2. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005;111:2837–49.
3. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747–62.
4. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet 2003;361:1843–8.
5. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003;362:772–6.
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55.
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with...
left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–21.
8. Bradley TD, Floras JS. Sleep apnea and heart failure: Part I: obstructive sleep apnea. Circulation 2003;107:1671–8.
9. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999;100:2332–5.
10. Takama N, Kurabayashi M. Effect of adaptive servo-ventilation on 1-year prognosis in heart failure patients. Circ J 2012;76:661–7.
11. Yoshihisa A, Suzuki S, Owada T, Iwaya S, Yamauchi H, Miyata M, et al. Short-term use of adaptive servo ventilation improves renal function in heart failure patients with sleep-disordered breathing. Heart Vessels 2013;28:728–34.
12. Sharma BK, Bakker JP, McSharry DG, Desai AS, Javaheri S, Malhotra A. Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a systematic review and meta-analysis. Chest 2012;142:1211–21.
13. Koyama T, Watanabe H, Tamura Y, Oguma Y, Kosaka T, Ito H. Adaptive servo-ventilation therapy improves cardiac sympathetic nerve activity in patients with heart failure. Eur J Heart Fail 2013;15:902–9.
14. Harada D, Joho S, Oda Y, Hirai T, Asanoh H, Inoue H. Short term effect of adaptive servo-ventilation on muscle sympathetic nerve activity in patients with heart failure. Auton Neurosci 2011;161:95–102.
15. Goso Y, Asanoh H, Ishise H, Kameyama T, Hirai T, Nozawa T, et al. Respiratory modulation of muscle sympathetic nerve activity in patients with chronic heart failure. Circulation 2001;104:418–23.
16. Scholte AJ, Schuif JD, Delgado V, Kok JA, Maan AC, et al. Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: Comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl Med Mol Imaging 2010;37:1698–705.
17. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Balduh S, Mashatte TL Jr, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 2014;63:141–9.
18. Travin MI. Clinical applications of myocardial innervation imaging. Cardiol Clin 2016;34:133–47.
19. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of (123)I-metaiodobenzylguanidine myocardial imaging for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 2013;6:772–84.
20. Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (1)(2)(3)I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging 2014;41:1673–82.
21. Travin MI, Henzlova MJ, van Eck-Smit BL, Jain D, Carvajal E, Folks RD, et al. Assessment of 123I-mIIBG and 99mTc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk. J Nucl Cardiol 2017;24:377–91.
22. Nakajima K, Nakata T. Cardiac 123I-MIBG imaging for clinical decision making: 22-Year experience in Japan. J Nucl Med 2015;56(Suppl 4):11–9s.
23. Yoshinaga K, Tomiyama Y, Manabe O, Kasai K, Katoh C, Magota K, et al. Prone-position acquisition of myocardial (123)I-metaiodobenzylguanidine (MIBG) SPECT reveals regional uptake similar to that found using (11)C-hydroxyephedrine PET/CT. Ann Nucl Med 2014;28:761–9.
24. Hall AB, Ziadie MC, Leech JA, Chen SY, Burwash IG, Renaud J, et al. Effects of short-term continuous positive airway pressure on myocardial sympathetic nerve function and energetics in patients with heart failure and obstructive sleep apnea: A randomized study. Circulation 2014;130:892–901.
25. Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol 2013;20:150–65.
26. Collop NA, Anderson WM, Boehlercke B, Claman D, Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007;3:737–47.
27. Sakakibara M, Yamada S, Kamiya K, Yokota T, Obu K, Tsutsui H. Sleep-disordered breathing is an independent risk factor of aborted sudden cardiac arrest in patients with coronary artery spasm. Circ J 2012;76:2204–10.
28. Nakajima K, Matsumoto N, Kasai T, Matsu S, Kiso K, Okuda K. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med 2016;30:188–99.
29. Mabuchi M, Imamura M, Kubo N, Morita K, Noriyasu K, Tsukamoto T, et al. Sympathetic denervation and reinervation after the maze procedure. J Nucl Med 2005;46:1089–94.
30. Aikawa T, Naya M, Obara M, Manabe O, Tomiyama Y, Magota K, et al. Impaired myocardial sympathetic innervation is associated with diastolic dysfunction in heart failure with preserved ejection fraction: 11C-hydroxyephedrine PET study. J Nucl Med 2017;58:784–90.
31. Schwager M, Kalff V, Rosenspire K, Haka MS, Molina E, Hutchins GD, et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990;82:457–64.
32. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP, et al. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941–73.
33. Ruehland WR, Rofford PD, O’Donoghue FJ, Pierce RJ, Singh P, Thornton AT. The new AASM criteria for scoring hypopnea: Impact on the apnea hypopnea index. Sleep 2009;32:150–7.
34. Koyama T, Watanabe H, Kobukai Y, Makabe S, Munehisa Y, Iino K, et al. Beneficial effects of adaptive servo ventilation in patients with chronic heart failure. Circ J 2010;74:2118–24.
35. Kasai T, Motwani SS, Yamino D, Gabriel JM, Montemurro LT, Amirthalingam V, et al. Contrasting effects of lower body positive pressure on upper airways resistance and partial pressure of carbon dioxide in men with heart failure and obstructive or central sleep apnea. J Am Coll Cardiol 2013;61:1157–66.
36. Momomura S, Seino Y, Kihara Y, Adachi H, Yasumura Y, Yokoyama H, et al. Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J 2015;79:981–90.
37. Tamaki S, Yamada T, Okuyama Y, Morita T, Sanada S, Tsukamoto Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: Results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009;53:426–35.
38. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with
peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759–66.
39. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579–90.
40. Verberne HJ, Somsen GA, Povinec P, van Eck-Smit BL, Jacobson AF. Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ((123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout. Eur J Nucl Med Mol Imaging 2009;36:1322–8.
41. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212–21.
42. Rischpler C, Fukushima K, Isoda T, Javadi MS, Dannals RF, Abraham R, et al. Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts. Eur J Nucl Med Mol Imaging 2013;40:1077–83.
43. Nomura Y, Matsunari I, Takamatsu H, Murakami Y, Matsuya T, Taki J, et al. Quantitation of cardiac sympathetic innervation in rabbits using 11C-hydroxyephedrine PET: Relation to 123I-MIBG uptake. Eur J Nucl Med Mol Imaging 2006;33:871–8.
44. Matsunari I, Aoki H, Nomura Y, Takeda N, Chen WP, Taki J, et al. Iodine-123 metaiodobenzylguanidine imaging and carbon-11 hydroxyephedrine positron emission tomography compared in patients with left ventricular dysfunction. Circ Cardiovasc Imaging 2010;3:595–603.
45. Hartmann F, Ziegler S, Nekolla S, Hadamitzky M, Seyfarth M, Richardt G, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: An analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart 1999;81:262–70.
46. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: An assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999;48:92–101.
47. Pierpont GL, DeMaster EG, Cohn JN. Regional differences in adrenergic function within the left ventricle. Am J Physiol 1984;246:H824–9.
48. Pierpont GL, DeMaster EG, Reynolds S, Pederson J, Cohn JN. Ventricular myocardial catecholamines in primates. J Lab Clin Med 1985;106:205–10.
49. Buckberg G, Hoffman JL. Right ventricular architecture responsible for mechanical performance: Unifying role of ventricular septum. J Thorac Cardiovasc Surg 2014;148:3166–71.
50. Bravo PE, Lautamaki R, Carter D, Holt DP, Nekolla SG, Dannals RF, et al. Mechanistic insights into sympathetic neuronal regeneration: Multitracer molecular imaging of catecholamine handling after cardiac transplantation. Circ Cardiovasc Imaging 2015;8
51. Fricke E, Eckert S, Dongas A, Fricke H, Preuss R, Lindner O, et al. Myocardial sympathetic innervation in patients with symptomatic coronary artery disease: Follow-up after 1 year with neurostimulation. J Nucl Med 2008;49:1458–64.
52. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E, et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 2015;373:1095–105.
53. Nakajima K, Scholte A, Nakata T, Dimitriu-Leen AC, Chikamori T, Vitolja JV, et al. Cardiac sympathetic nervous system imaging with 123I-metaiodobenzylguanidine: Perspectives from Japan and Europe. J Nucl Cardiol 2017;24:952–60.